Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study

BACKGROUND/AIMS: Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, real-world clinical data regarding this drug are scarce. We aimed to compare the Helicobacter pylori eradication rates of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Yoon Suk, Kim, Sunyong, Kim, Hyun-Young, Noh, Seung Jae, Park, Jung Ho, Sohn, Chong Il, Park, Chan Hyuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502490/
https://www.ncbi.nlm.nih.gov/pubmed/36510776
http://dx.doi.org/10.5009/gnl220218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502490/
https://www.ncbi.nlm.nih.gov/pubmed/36510776
http://dx.doi.org/10.5009/gnl220218

Ejemplares similares